Acer Therapeutics announces update on OLPRUVA commercial launch

Acer Therapeutics announced an update on progress in support of its commercial launch of OLPRUVA for oral suspension, including drug availability now expected earlier than anticipated in mid-June 2023, subject to additional capital. "Since the U.S. FDA approval of OLPRUVA(TM) at the end of 2022, we and our partners have been working diligently to bring this innovative treatment option to UCD patients in need as soon as possible," said Chris Schelling, CEO and Founder of Acer. "As a result of these efforts, I am pleased to report we are ahead of our anticipated launch schedule and now expect drug availability beginning in mid-June 2023. We have also made significant progress in our ongoing discussions with payers regarding reimbursement, increased physician awareness and interest, and built out our patient support and fulfillment program. We look forward to continued progress across these and other launch initiatives and to delivering OLPRUVA to patients starting in mid-June 2023, subject to additional capital."